[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].

@article{Ueyama2012TreatmentWA,
  title={[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].},
  author={Jun-ichi Ueyama and Akira Kure and Keisuke Okuno and Hitoshi Sano and Naohiro Tamoto and Susumu Kanzaki},
  journal={[Rinsho ketsueki] The Japanese journal of clinical hematology},
  year={2012},
  volume={53 4},
  pages={460-4}
}
Translocation (8;21)/AML1-ETO is considered a favorable cytogenetic abnormality in acute myeloid leukemia (AML). However, the outcomes associated with KIT mutations in AML1-ETO have not been elucidated. A 16-year-old boy was diagnosed with recurrent AML. Although he underwent hematopoietic stem cell transplantation (HSCT) twice, the leukemia relapsed and… CONTINUE READING